FeesSafety
Pluang+

Bristol-Myers Squibb raises 2026 earnings guidance amid strong growth in new medicines.

Company Fundamentals
18 Nov 2026, 22:00 WIB
The Motley Fool
View Source
Bullish
Bristol-Myers Squibb raises 2026 earnings guidance amid strong growth in new medicines.

Bristol-Myers Squibb reported a 12% revenue increase in its growth portfolio to $7.7 billion for Q3 2026, driven by eight medicines each generating over $1 billion annually. The company advanced four late-stage clinical trials, including FDA clearance for a new multiple myeloma therapy, supporting future growth. Cost-saving initiatives are expected to save $2 billion, helping maintain margins despite upcoming patent expirations. Management raised full-year adjusted EPS guidance to $6.35-$6.55, signaling confidence in sustained momentum and long-term growth potential.

Bristol-Myers Squibb (BMY) trades at USD 59.94 on Pluang as of Nov 19, 2026 03:21 WIB, down 2.31% in one day. The stock's market cap stands at $125.40 billion, with a dividend yield of 4.11%. Despite recent selling pressure, typical hold time on Pluang is 91 days, showing moderate investor interest.

More News (BMY)

banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App